Deposition, Imaging, and Clearance: What Remains to be Done?-Reference-Cited by-同舟云学术

Deposition, Imaging, and Clearance: What Remains to be Done?

Published:2010-12 Issue:S2 Volume:23 Page:S-39-S-57
ISSN:1941-2711
Container-title:Journal of Aerosol Medicine and Pulmonary Drug Delivery
language:en
Short-container-title:Journal of Aerosol Medicine and Pulmonary Drug Delivery

Author:

Scheuch Gerhard¹,Bennett William²,Borgström Lars³,Clark Andy⁴,Dalby Richard⁵,Dolovich Myrna⁶,Fleming John⁷,Gehr Peter⁸,Gonda Igor⁹,O'Callaghan Chris¹⁰,Taylor Glyn¹¹,Newman Steve¹²

Affiliation:

1. Activaero GmbH, Gemünden, Germany.

2. Department of Medicine, Division of Pulmonary Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

3. AstraZeneca R&D, Lund, Sweden.

4. Novartis Pharmaceuticals, San Carlos, California.

5. University of Maryland, School of Pharmacy, Baltimore, Maryland.

6. Faculty of Sciences, Michael de Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

7. Southampton University Hospitals NHS Trust, Southampton, United Kingdom.

8. Institute of Anatomy, University of Bern, Bern, Switzerland.

9. Aradigm Corporation, Hayward, California.

10. Division of Child Health, Institute of Lung Health, Department of Infection, Inflammation and Immunity, University of Leicester, Leicester, United Kingdom.

11. Cardiff Scintigraphics and Welsh School of Pharmacy, Cardiff, United Kingdom.

12. Scientific Consultant, Hunstanton, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmaceutical Science,Pulmonary and Respiratory Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/jamp.2010.0839

Reference119 articles.

1. Measuring Total and Regional Lung Deposition Using Inhaled Radiotracers

2. Methods to identify drug deposition in the lungs following inhalation

3. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications